Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology
DAEJEON, South Korea, Nov. 10, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the company has entered into an exclusive license agreement with Daiichi Sankyo (TSE: 4568). Under the terms of the agreement, Daiichi Sankyo will acquire world-wide rights to use ALT-B4, Alteo...
Alteogen Receives Ministry of Food and Drug Safety (MFDS) Approval for Tergase®
* Tergase® poised to capture a fair share of the global hyaluronidase market.
DAEJEON, South Korea, July 8, 2024 /PRNewswire/ -- Alteogen Inc.
Altos Biologics Files for Approval of Aflibercept Biosimilar
DAEJEON, South Korea, July 1, 2024 /PRNewswire/ -- Alteogen Inc.
Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile
Alteogen expects Tergase® will replace commercially available animal-derived hyaluronidase products and their significant disadvantages. Compared with other commercially available hyaluronidase products, Tergase® showed no incidence of anti-drug antibodies (ADA). The occurrence of ADA is known ...
Altos Biologics, a Subsidiary of Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical Trial of Eylea® Biosimilar in Neovascular Age-related Macular Degeneration
* Altos Biologics, a subsidiary of Alteogen, is actively engaged in Eylea® Biosimilar (ALT-L9) clinical development and licensing-out discussions. * Early 2024 projected for Phase 3 completion and product launch in Europe expected after obtaining approval in the first half of 2025. DAEJEON, So...
